Johnson & Johnson is exploring a potential $20B+ sale of its orthopedics unit DePuy Synthes instead of spinning it off, drawing interest from private equity firms in a major healthcare deal.
Johnson & Johnson reports Q4 earnings of $2.46/share, beating estimates with 9.1% sales growth to $24.6B, but stock falls 3% on Stelara patent loss concerns.
Johnson & Johnson's (JNJ) Tecvayli-Darzalex combination shows strong Phase 3 results in multiple myeloma, creating competitive pressure for CAR-T therapies like Carvykti (LEGN) while offering new treatment options.
Bayer's asundexian succeeds in Phase 3 stroke prevention trial, becoming first FXIa inhibitor to show positive results and potentially opening door for safer blood clot medications.
Johnson & Johnson acquires Halda Therapeutics for $3.05B, gaining innovative prostate cancer treatment and platform technology for multiple solid tumors.
Bristol Myers Squibb and Johnson & Johnson have stopped a major Phase 3 trial of milvexian for acute coronary syndrome after an interim review showed the drug is unlikely to meet its main goals. Other trials continue with results expected in 2026.
